Suppression of bone density loss and bone turnover in patients with hormone‐sensitive prostate cancer and receiving zoledronic acid

To report a randomized, placebo‐controlled study of treatment with zoledronic acid every 3 months in patients with hormone‐sensitive prostate cancer, both with and without bone metastases, to assess the effect on bone mineral density (BMD) and markers of bone turnover.

[1]  C. Ryan,et al.  Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. , 2006, The Journal of urology.

[2]  J. Doroshow,et al.  A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases , 2006, Clinical Cancer Research.

[3]  M. Dimopoulos,et al.  Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Polascik,et al.  Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. , 2005, Urology.

[5]  P. Walsh.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The Journal of urology.

[6]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Saad,et al.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.

[8]  M. Michaelson,et al.  Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer , 2004, Clinical Cancer Research.

[9]  R. Coleman,et al.  Bone resorption predicts for skeletal complications in metastatic bone disease , 2003, British Journal of Cancer.

[10]  J. Eastham,et al.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. , 2003, The Journal of urology.

[11]  Hsi-Chin Wu,et al.  Lumbar Bone Mineral Density in Prostate Cancer Patients with Bone Metastases , 2003, Endocrine research.

[12]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[13]  P. Kantoff,et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.

[14]  R. Rizzoli,et al.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.

[15]  M. Koizumi,et al.  Correlation between bone metabolic markers and bone scan in prostatic cancer. , 1997, The Journal of urology.